ARDANA APPOINTS NEW NON-EXECUTIVE
TO THE BOARD

Edinburgh, UK: 29 June 2006: Ardana, the company focused on improving human reproductive health, today announces that Huw Jones has been appointed as a non-executive director.

Huw Jones was awarded a PhD in Pharmacology 1986. After a short period of postdoctoral research, he joined Smith Kline & French UK in a commercial role in 1986. During his eleven-year career at SK&F and SmithKline Beecham he migrated through a number of sales, marketing, business development and new product development roles of increasing seniority. He was appointed UK Marketing Director in 1996.

Huw moved to Elan Corporation PLC in 1997. In 1998 he was appointed Vice-President and Managing Director, UK and in 2001 was appointed Senior Vice President, Northern Europe, responsible for operations in Germany, France, Ireland, the UK and for establishing companies in Benelux.

In 2002 he co-founded Daffodil Consulting LLP which specialises in providing strategic advice on Europe to biopharmaceutical companies. Daffodil Consulting was asked to establish the European affiliate for CV Therapeutics Inc (NASDAQ, CVTX) in late 2002. Huw served as President, Europe, for CV Therapeutics between 2002 and 2006. He is also Non-Executive Chairman of Ashbourne Pharmaceuticals.

Maureen Lindsay, CEO of Ardana, said:

“Huw brings considerable sales and marketing expertise to our Board and we are delighted that he is joining us. He has an impressive background and his current directorships demonstrate how highly he is valued in an advisory capacity. His contributions will be invaluable as we grow our commercial product pipeline across Europe.”

.

-- ENDS --

back to top